Briant Fruth

3.1k total citations
28 papers, 781 citations indexed

About

Briant Fruth is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Briant Fruth has authored 28 papers receiving a total of 781 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in Briant Fruth's work include Lung Cancer Research Studies (5 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Cancer Treatment and Pharmacology (4 papers). Briant Fruth is often cited by papers focused on Lung Cancer Research Studies (5 papers), Pancreatic and Hepatic Oncology Research (5 papers) and Cancer Treatment and Pharmacology (4 papers). Briant Fruth collaborates with scholars based in United States, Canada and Australia. Briant Fruth's co-authors include Donna Niedzwiecki, Alan P. Venook, Charles Erlichman, Rafaël Fonseca, A. Keith Stewart, Jeffrey A. Zonder, Shaji Kumar, Natalie S. Callander, Betsy LaPlant and Wee Joo Chng and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Briant Fruth

27 papers receiving 769 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Briant Fruth United States	10	547	281	175	169	152	28	781
Jeff White United Kingdom	16	363 0.7×	279 1.0×	73 0.4×	332 2.0×	209 1.4×	53	898
Stephan D. Thomé United States	9	829 1.5×	177 0.6×	365 2.1×	182 1.1×	204 1.3×	21	1.1k
Geoffrey Chong Australia	15	393 0.7×	117 0.4×	307 1.8×	151 0.9×	94 0.6×	59	769
В. С. Медведев Russia	4	397 0.7×	242 0.9×	99 0.6×	207 1.2×	97 0.6×	11	950
Sheng Yang China	16	406 0.7×	196 0.7×	289 1.7×	149 0.9×	58 0.4×	105	781
Jiwon Koh South Korea	18	663 1.2×	364 1.3×	216 1.2×	192 1.1×	146 1.0×	73	1.0k
John Frye United States	10	286 0.5×	172 0.6×	101 0.6×	222 1.3×	86 0.6×	24	754
Jeltje F. de Vries Netherlands	10	747 1.4×	669 2.4×	62 0.4×	122 0.7×	80 0.5×	15	1.2k
Hari Menon India	14	233 0.4×	189 0.7×	176 1.0×	119 0.7×	49 0.3×	73	633
Nathalie Théou–Anton France	14	362 0.7×	322 1.1×	52 0.3×	127 0.8×	79 0.5×	28	666

Countries citing papers authored by Briant Fruth

Since Specialization

Citations

This map shows the geographic impact of Briant Fruth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Briant Fruth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Briant Fruth more than expected).

Fields of papers citing papers by Briant Fruth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Briant Fruth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Briant Fruth. The network helps show where Briant Fruth may publish in the future.

Co-authorship network of co-authors of Briant Fruth

This figure shows the co-authorship network connecting the top 25 collaborators of Briant Fruth. A scholar is included among the top collaborators of Briant Fruth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Briant Fruth. Briant Fruth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vaz-Luís, Inês, Graziella Mazza, Angela DeMichele, et al.. (2025). 485MO Health-related quality of life (HRQoL) from the PATINA trial (AFT-38): Impact of adding palbociclib to HER2 and endocrine therapy (ET) after induction in HR+/HER2+ metastatic breast cancer (MBC). Annals of Oncology. 36. S378–S378. 1 indexed citations

Dueck, Amylou C., Briant Fruth, Susan Geyer, et al.. (2025). Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602).. Journal of Clinical Oncology. 43(16_suppl). 4020–4020.

Ganti, Apar Kishor, Briant Fruth, Andreas Rimner, et al.. (2024). Quality of life outcomes in patients participating in the CALGB 30610 trial (CALGB 70702): Alliance. Cancer. 131(1). e35663–e35663. 1 indexed citations

Sukrithan, Vineeth, Briant Fruth, Rui Qin, et al.. (2023). A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocrine Related Cancer. 30(11). 4 indexed citations

Tella, Sri Harsha, Nathan R. Foster, Qian Shi, et al.. (2023). Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma. The Oncologist. 28(10). 917–e966. 1 indexed citations

Mutter, Robert W., Briant Fruth, Nicholas B. Remmes, et al.. (2023). Abstract GS4-05: Phase II randomized trial of conventional versus hypofractionated post-mastectomy proton radiotherapy. Cancer Research. 83(5_Supplement). GS4–5. 1 indexed citations

Warsame, Rahma, Joselle Cook, Briant Fruth, et al.. (2022). A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncology. Contemporary Clinical Trials Communications. 29. 100964–100964. 5 indexed citations

Ganti, Apar Kishor, Amylou C. Dueck, Briant Fruth, et al.. (2022). Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (Alliance, Sub-study CALGB 70702).. Journal of Clinical Oncology. 40(16_suppl). 8504–8504. 2 indexed citations

Daniel, J., Katharine A. Price, Eric J. Moore, et al.. (2022). Non-Inferiority Margin and Nodal Analysis of De-Escalated Adjuvant Radiation Therapy (DART) for HPV-Related Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Preplanned Pooled Analysis of MC1273 & MC1675. International Journal of Radiation Oncology*Biology*Physics. 112(5). e3–e4. 5 indexed citations

10.

Sharma, Akanksha, Briant Fruth, Maciej Mrugala, et al.. (2021). How much time do we have? Longitudinal perception of prognosis in newly-diagnosed high grade glioma patients and caregivers compared to clinicians. Journal of Neuro-Oncology. 152(2). 313–323. 15 indexed citations

11.

Goodman, Karyn A., Fang‐Shu Ou, Nathan C. Hall, et al.. (2021). Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial. Journal of Clinical Oncology. 39(25). 2803–2815. 71 indexed citations

12.

Chakrabarti, Sakti, Tyler Zemla, Daniel H. Ahn, et al.. (2019). Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. The Oncologist. 25(5). 380–e763. 10 indexed citations

13.

Pachman, Deirdre R., Travis Dockter, Patricia J. Zekan, et al.. (2017). A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. Supportive Care in Cancer. 25(11). 3407–3416. 50 indexed citations

14.

Guercio, Brendan J., Alan P. Venook, Donna Niedzwiecki, et al.. (2017). Associations of physical activity with survival and progression in metastatic colorectal cancer: Results from CALGB 80405 (Alliance).. Journal of Clinical Oncology. 35(4_suppl). 659–659. 2 indexed citations

15.

Venook, Alan P., Donna Niedzwiecki, Federico Innocenti, et al.. (2016). Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. Journal of Clinical Oncology. 34(15_suppl). 3504–3504. 246 indexed citations

16.

Merchan, Jaime R., Rui Qin, Henry C. Pitot, et al.. (2015). Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study. Cancer Chemotherapy and Pharmacology. 75(3). 485–493. 14 indexed citations

17.

Kulke, Matthew H., Donna Niedzwiecki, Nathan R. Foster, et al.. (2015). Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).. Journal of Clinical Oncology. 33(15_suppl). 4005–4005. 58 indexed citations

18.

Kumar, Shaji, Betsy LaPlant, Wee Joo Chng, et al.. (2014). Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 125(3). 443–448. 200 indexed citations

19.

Einstein, Mark H., Robert M. Wenham, Robert J. Morgan, et al.. (2012). Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer.. Journal of Clinical Oncology. 30(15_suppl). 5025–5025. 13 indexed citations

20.

Stewart, A. Keith, Suzanne Trudel, Jeffrey A. Zonder, et al.. (2012). Phase I trial of obatoclax mesylate in combination with bortezomib for treatment of relapsed multiple myeloma.. Journal of Clinical Oncology. 30(15_suppl). 8013–8013. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact